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Introduction
The genetic disease ataxia-telangiectasia (A-T) is charac-
terized by hypersensitivity to ionizing radiation, by genomic
instability, and by predisposition to cancer, especially
breast cancer. Early reports estimated that 3.8% of breast
cancer cases could be attributed to ataxia-telangiectasia
mutated (ATM) heterozygosity, with a possible range of
1–13%. If, as some evidence suggests, missense muta-
tions may be responsible for the majority of breast cancer
among  ATM heterozygotes [1], then these often cited
figures underestimate the actual prevalence of the gene
since they were derived from studies of A-T patients
where the prevalence of truncating mutations is high and
the prevalence of missense mutations is low. Furthermore,
although inconsistent, some studies suggest that the ATM
gene may be associated with an increased risk of breast
cancer as high as 15-fold [2–12].
This possible excess risk of breast cancer associated with
ATM heterozygosity, and the known biochemical interac-
tions between the protein products of the ATM  and
BRCA1 genes, are the basis for several genetic epidemio-
logic studies designed to reconcile these conflicting
results and to clarify the role that the ATM gene plays in
the etiology of breast cancer and other cancers. The inter-
national, multidisciplinary, National Cancer Institute-spon-
sored workshop was organized as a forum for discussion
of these ongoing and planned epidemiological studies.
The 45 invited participants are key collaborators on these
studies, with expertise including molecular and clinical
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genetics, radiation biology and physics, epidemiology, bio-
statistics, pathology, and medicine. The following is a
summary of projects presented.
The Women’s Environmental, Cancer, and
Radiation Epidemiology study
JL Bernstein (Mount Sinai School of Medicine, New York,
USA) presented an overview of the Women’s Environmen-
tal, Cancer, and Radiation Epidemiology (WECARE) study
(NCI-CA83178; for study investigators, see Appendix). The
WECARE study (http://146.203.34.23/atmstudy/front.html)
is an international, multicenter, population-based, genetic
epidemiological study designed to test the hypothesis that
the incidence of contralateral breast cancer is increased
among women who are heterozygous for ATM and who
received radiation therapy as treatment for their first primary
breast cancer. The 700 ‘cases’ are women with bilateral
breast cancer, and the 1400 individually counter-matched
‘controls’ are women with unilateral breast cancer being
identified and interviewed through population-based tumor
registries in the United States and in Denmark.
The full spectrum of ATM mutations is examined using an
efficient staged approach (denaturing high-performance
liquid chromatography followed by sequencing), which
has been standardized in all four laboratories performing
the analyses. Lifetime exposure to radiation, including the
radiation therapy scatter dose to the contralateral breast,
is also assessed. The study’s premise is that any important
genetic factors (e.g. ATM gene mutations) and etiological
factors for breast cancer (e.g. radiation exposure) will be
more prevalent among women who already have a first
primary cancer than they would be among women in the
general population. The WECARE study thus presents a
promising context for sorting out complex gene–environ-
ment interactions involved in breast carcinogenesis.
Breast cancer incidence among A-T family
members
The overall objective of this study, as presented by R Haile
(University of Southern California, Los Angeles, CA, USA;
for study investigators see Appendix), is to determine
whether subjects who are ATM  heterozygotes have a
higher than expected risk of cancer, with a primary focus
on breast cancer. Collaborators in Argentina, Bulgaria,
Canada, Costa Rica, Germany, Israel, Italy, Turkey, and
the United States who have already identified A-T families
are collecting and verifying the reported history of cancer
in parents and grandparents of A-T cases. In addition,
genetic testing for mutations in the ATM  gene in these
families will be conducted. Participating centers have at
present collectively identified 461 A-T families. Also
planned are exploratory analyses addressing the issue of
the heterogeneity of risk between subgroups defined by
country of origin and specific type of mutation. It is under-
stood that an analysis combining all known data sets will
be necessary to address questions of heterogeneity in an
informative manner.
ATM variants and breast cancer risk among
women at high risk for breast cancer
G Chenevix-Trench (Queensland Institute of Medical
Research, Brisbane, Australia; for study investigators see
Appendix) discussed studies of A-T families that suggest
female obligate heterozygotes have an increased risk of
breast cancer. Yet neither linkage analyses or mutation
studies have provided supporting evidence for these studies.
Two recurrent mutations, 7271T>G and IVS10-6T>G,
conferring an elevated risk were recently reported. These
mutations were examined in a population-based, case–
control series of breast cancer patients as well as in multi-
ple-case breast cancer families. They found three multiple-
case families in which one or other of these mutations
segregated with breast cancer. The estimated average
penetrance of these mutations was 60% (95% confi-
dence interval, 32–90%) up to age 70 years, equivalent to
a 16-fold (95% confidence interval, 6–38) increased risk.
Functional analyses in heterozygous cell lines indicated
that both mutations act in a dominant-negative manner.
The conclusion was that certain ATM gene mutations, mis-
sense and truncating, are associated with a sufficiently
high risk of breast cancer and that they can be found in
multiple-case breast cancer families. These families also
contained multiple cases of colorectal and gastric cancer,
raising the possibility that these mutations also confer high
risks for these cancer types.
Full mutation analysis of the ATM gene is now underway in
a large panel of non-BRCA1/BRCA2 breast cancer fami-
lies, as are kinase assays of lymphoblastoid cell lines from
these families as a screen for dominant-negative mutations.
Radiation exposure, ATM gene mutations and
breast cancer risk
The extent to which ATM heterozygosity increases the risk
of radiation-induced breast cancer is currently being
explored, as presented by A Broeks (The Netherlands
Cancer Institute, Amsterdam, The Netherlands; for study
investigators see Appendix).
Three case–control studies were conducted, with cases
defined as patients who developed breast cancer following
therapeutic or diagnostic radiation before age 50 years.
Study 1 consisted of 58 patients with contralateral breast
cancer following therapeutic radiation for their first breast
cancer. Study 2 included 40 patients with breast cancer
following mantle-field irradiation for Hodgkin’s disease.
Finally, study 3 involved 30 patients who developed breast
cancer after diagnostic mammographic screening following
a diagnosis of benign breast disease. For each case, four251
age-matched controls were selected who received radia-
tion exposure for the same disease or diagnostic proce-
dure but who did not develop breast cancer.
The proportions of ATM heterozygotes were determined
using the denaturing gradient gel electrophoresis mutation
detection method. In study 1, a substantial number of ATM
protein truncating mutations and a variety of missense
mutations were detected, both among the cases and the
control individuals. In a case–control setting, taking all risk
factors into account, the results of these three studies
were analyzed. It appears that ATM heterozygotes may
have an increased risk (relative risk, 3.1) of developing a
specific type of breast cancer, characterized by frequent
bilateral occurrence, by early age at onset, and by long-
term survival.
Role of the ATM gene in breast tumor
development and radiation sensitivity
The expression of the ATM and p53 proteins has been
studied in breast in situ carcinomas and in invasive carci-
nomas. The results presented by J Hall (International
Agency for Research on Cancer, Lyon, France; for study
investigators see Appendix) indicate that, in most of the
sporadic breast carcinomas, the DNA damage response
as well as also other signaling pathways activated by the
ATM and p53 multifunctional proteins [13] were compro-
mised. Consistent with this, ATM expression was dramati-
cally reduced in approximately 30% of sporadic breast
neoplasms [14]. The expression profiles of these and
other proteins implicated in DNA double-strand break
repair (BRCA1, NBS1, MRE11 and Rad50) are presently
being assessed in breast tumors.
Additionally, molecular characterization of lymphoblastoid
cell lines established from radiosensitive and nonradiosen-
sitive patients is being used to investigate the role of alter-
ations in the ATM gene as a risk factor in breast cancer
development. In some cell lines, the level of cell survival
and p53 induction after ionizing radiation exposure is
lower than that observed in control cell lines, indicating an
alteration in the ATM signaling pathway. Using the protein
truncating tests and restriction endonuclease fingerprint-
ing techniques, a variety of rare ATM sequence alterations
and polymorphisms have been detected in cases. The fre-
quency of these alterations and polymorphisms in control
samples is under investigation to establish whether their
presence is associated with either radiation sensitivity or
increased breast cancer risk.
Conclusions
The primary purpose of this meeting was to bring together
scientists from diverse disciplines who are currently
engaged in research aimed at understanding the complex-
ities of the ATM gene and its role in breast carcinogene-
sis. The encouraging preliminary results presented,
coupled with the long-term opportunities afforded from
these studies and the recent advances in genomics and
molecular genetics technology, set the stage for reconcil-
ing the conflicting results of prior genetic and epidemio-
logic studies. It is the scientists’ joint goal that these
studies contribute to our understanding, in order to cor-
rectly assess the population frequency of various types of
ATM mutations, to determine the correlation between
ATM genotype and the breast (or other) cancer pheno-
type, to clarify the function of the A-T gene product within
the radiation damage repair pathways and, importantly, to
precisely identify major genetic and environmental effect
modifiers. In turn, this information will allow direct evalua-
tion of the proportion of breast cancer directly related to
mutations in the ATM gene (population attributable risk),
and will facilitate the design of appropriate preventive and
therapeutic strategies targeted to a population at
increased risk for developing breast cancer.
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WECARE Study Collaborative Group
Principal Investigator
Jonine L Bernstein (Mount Sinai School of Medicine, New
York, USA).
Co-Principal Investigators
W Douglas Thompson, Chair of the Epidemiology and
Biostatistics Core (University of Southern Maine, Portland,
ME, USA), Robert W Haile (University of Southern Califor-
nia, Los Angeles, CA, USA), Leslie Bernstein, Chair of the
Data Collection Core (University of Southern California,
Los Angeles, CA, USA), and Patrick J Concannon, Chair
of the Laboratory Core (Virginia Mason Research Center,
Seattle, WA, USA).
Coordinating Centers
Susan L Teitelbaum (Project Director), Gertrud S Berkowitz
(Epidemiologist), Xiaolin Liang (Informatics Specialist),
Monica Katyal (Project Coordinator), and Stephanie Skoler
(Project Coordinator) (Mount Sinai School of Medicine,
New York, USA); Daniela Seminara (Program Officer)
(National Cancer Institute, Bethesda, MD, USA).
Laboratories
Sharon Teraoka (Laboratory Director) (Virginia Mason
Research Center, Seattle, WA, USA); Anh T Diep (Labora-
tory Director), Nianmin Zhou (Laboratory Manager), and
Yong Liu (Director of Blood Processing) (University of
Southern California, Los Angeles, CA, USA); Anne-Lise
Børresen-Dale (Laboratory Director), and Laila Jansen (Lab-
oratory Manager) (Norwegian Radium Hospital, Oslo,
Norway); Barry S Rosenstein (Laboratory Director), and
David P Atencio (Laboratory Manager) (Mount Sinai School
of Medicine, New York, USA); Richard A Gatti (Consultant)
(University of California at Los Angeles, CA, USA).
Data Collection Centers
Laura Donnelly (Project Manager), and Maya Mahue-
Giangreco (Project Manager) (University of Southern Cali-
fornia, Los Angeles, CA, USA); Jørgen H Olsen (Director),
and Lene Mellemkjær (Project Manager) (Danish Cancer
Society, Copenhagen, Denmark); Kathleen E Malone
(Director), and Noemi Epstein (Project Manager) (Fred
Hutchinson Cancer Research Center, Seattle, WA, USA);
Hoda Anton-Culver (Director), and Joan Largent (Project
Manager) (University of California at Irvine, Irvine, CA,
USA); Charles F Lynch (Director), and Jeanne DeWall
(Project Manager) (University of Iowa, Iowa City, IA, USA).
Radiation Core
Marilyn Stovall (Dosimetry Laboratory Director and Chair,
Radiation Core) (University of Texas, MD Anderson Cancer
Center, Houston, TX, USA); Roy E Shore (Epidemiologist)
(New York University, New York, USA); John D Boice Jr
(Consultant) (International Epidemiology Institute, Rockville,
MD, and Vanderbilt University, Nashville, TN, USA).
Epidemiology and Biostatistics Core
Duncan C Thomas, and Bryan M Langholz (University of
Southern California, Los Angeles, CA, USA).
Breast cancer incidence among A-T family
members study investigators
Robert W Haile, Duncan C Thomas, and Leslie Bernstein
(University of Southern California, Los Angeles, CA, USA);
Richard A Gatti (University of California at Los Angeles,
Los Angeles, CA, USA).
ATM variants and breast cancer risk among
women at high risk for breast cancer study
investigators
G Chenevix-Trench, D Nyholt, and KK Khanna (Queens-
land Institute of Medical Research, Brisbane, Australia); A
Jenkins, and JL Hopper (The University of Melbourne,
Centre for Genetic Epidemiology, Victoria, Australia); C
Scott, andJ Sambrook(Peter MacCallum Cancer Institute,
Victoria, Australia); T Dörk (Medical School Hannover,
Hannover, Germany).
Radiation exposure, ATM gene mutations and
breast cancer risk study investigators
Annegien Broeks (Division of Experimental Therapy), Flora
E van Leeuwen (Department of Epidemiology), and Laura J
van’t Veer (Department of Pathology) (The Netherlands
Cancer Institute, Amsterdam, The Netherlands).
Role of the ATM gene in breast tumor
development and radiation sensitivity study
investigators
Janet Hall, Sandra Angèle, Michèle Vuillaume, and
Philippe Tanière (International Agency for Research on
Cancer, Lyon, France); Isabelle Treilleux, and Alain
Brémond (Centre Régional Léon Bérard, Lyon, France);
Jean-Pierre Gérard, and Pascale Romestaing (Service de
Radiothérapie-Oncologie, Centre Hospitalier Lyon Sud,
Pierre Bénite, France).
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